Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,022.21 -29.20 (-0.58%) Dow
37,753.31 -45.66 (-0.12%) Nasdaq
15,683.37 -181.88 (-1.15%) Bitcoin USD
61,485.63 -1,860.84 (-2.94%) CMC Crypto 200
885.54 0.00 (0.00%)
PMV Pharmaceuticals, Inc. (PMVP)
After hours:
| Previous close | 1.6000 |
| Open | 1.6000 |
| Bid | 1.5600 x 100 |
| Ask | 1.6600 x 100 |
| Day's range | 1.6000 - 1.6600 |
| 52-week range | 1.1750 - 9.7200 |
| Volume | |
| Avg. volume | 588,975 |
| Market cap | 82.824M |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4400 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.75 |
GlobeNewswirePMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS WT advanced solid tumors PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm
- GlobeNewswire
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual MeetingOf the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response with a seven-month median duration of response and a favorable safety profileRezatapopt is a first-in-class precision oncolo
- GuruFocus.com
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
Strategic Focus on Rezatapopt Advances as Company Extends Cash Runway
